- {{heading}}
- Ab00239-2.0 Anti-Amyloid beta (aa 4-10) [WO2]
- Human
- Mouse IgG2a
- Purified
- In Stock
- Ab00239-23.0 Anti-Amyloid beta (aa 4-10) [WO2]
- Human
- Rabbit IgG
- Purified
- In Stock
Recombinant monoclonal antibody to Amyloid beta (aa 4-10). Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma WO2.
UniProt Accession Number of Target Protein: P05067
Alternative Name(s) of Target: Abeta
Immunogen: Synthetic peptides, corresponding to amino acids 1-42 of human beta amyloid, conjugated to KLH.
Specificity: Recognises amino acid residues 4-10 of human Amyloid β.
Application Notes: This antibody binds to amyloid beta peptides and may be used in Western Blotting as well as ELISA and IHC. Youn et al. (PMID: 31077246) describes the use of an HRP-conjugate of the IgG2a version of WO2 in a diagnostic Multimer Detection System-Oligomeric Amyloid-β assay to measure oligomerization tendencies in the blood.
Antibody first published in:
Ida et al. Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay J Biol Chem. 1996 Sep 13;271(37):22908-14 PMID:8798471
Note on publication:
Describes the generation and characterization of the WO2 clone.
Comparison of recombinant WO2 anti-Amyloid beta (Ab00239-2.0) with hybridoma-derived WO2 from Competitor M. Panel A shows a Coomassie Blue-stained SDS-PAGE gel comparing Absolute Antibody’s recombinant WO2 with antibody from the corresponding hybridoma under native and reducing (DTT) conditions. Both preparations showed, by this method, comparative purity. Subsequently, the specificity of the antibodies was tested in assays detecting immobilised peptides (see B), in particular various Amyloid-beta derived peptides probed with WO2 (50 ng/ml) and a goat-anti-mouse peroxidase conjugated tracer as shown in C. The recombinant and hybridoma-derived antibody showed comparative selectivity, however higher signal intensity. Titration of recombinant and hybridoma derived WO2 against Aß 2-42 (D)and Aß 3-42(E) indicates that the recombinant antibody has higher activity than the hybridoma-derived counterpart.
Comparison of recombinant WO2 anti-Amyloid beta (Ab00239-2.0) with hybridoma-derived WO2 from Competitor M. Panel A shows a Coomassie Blue-stained SDS-PAGE gel comparing Absolute Antibody’s recombinant WO2 with antibody from the corresponding hybridoma under native and reducing (DTT) conditions. Both preparations showed, by this method, comparative purity. Subsequently, the specificity of the antibodies was tested in assays detecting immobilised peptides (see B), in particular various Amyloid-beta derived peptides probed with WO2 (50 ng/ml) and a goat-anti-mouse peroxidase conjugated tracer as shown in C. The recombinant and hybridoma-derived antibody showed comparative selectivity, however higher signal intensity. Titration of recombinant and hybridoma derived WO2 against Aß 2-42 (D)and Aß 3-42(E) indicates that the recombinant antibody has higher activity than the hybridoma-derived counterpart.
Comparison of recombinant WO2 anti-Amyloid beta (Ab00239-2.0) with hybridoma-derived WO2 from Competitor M. Panel A shows a Coomassie Blue-stained SDS-PAGE gel comparing Absolute Antibody’s recombinant WO2 with antibody from the corresponding hybridoma under native and reducing (DTT) conditions. Both preparations showed, by this method, comparative purity. Subsequently, the specificity of the antibodies was tested in assays detecting immobilised peptides (see B), in particular various Amyloid-beta derived peptides probed with WO2 (50 ng/ml) and a goat-anti-mouse peroxidase conjugated tracer as shown in C. The recombinant and hybridoma-derived antibody showed comparative selectivity, however higher signal intensity. Titration of recombinant and hybridoma derived WO2 against Aß 2-42 (D)and Aß 3-42(E) indicates that the recombinant antibody has higher activity than the hybridoma-derived counterpart.